CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 46 target
Drug / intervention
camrelizumab in combination with nab-paclitaxel and famitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04129996
NCT04129996Phase 2Unknown
CompareCT.gov

Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer: An Open, Single-arm, Multicenter, Efficacy and Safety Phase II Clinical Study.

Fudan University·interventional·Posted Oct 17, 2019·Updated Jan 11, 2022

In Brief

A Phase 2 clinical trial evaluating camrelizumab in combination with nab-paclitaxel and famitinib for Triple-Negative Breast Cancer. Targeting 46 participants across 1 site.

Detailed Summary

The study is being conducted to evaluate the efficacy, safety of camrelizumab in combination with nab-paclitaxel and famitinib in Patients with unresectable locally advanced or metastatic immunomodulatory triple negative breast Cancer..

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple-Negative Breast Cancer
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
2020202120222023202420252026
First PostedOct 17, 2019
Enrollment StartOct 1, 2019
Primary CompletionSep 1, 2022
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 6.7 years ago

Interventions

camrelizumab in combination with nab-paclitaxel and famitinibdrug

camrelizumab in combination with nab-paclitaxel and famitinib for triple negative breast cancer